Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001872|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : October 12, 2018
Blood contains different kinds of cells, white blood cells, red blood cells, and platelets. In order to treat certain diseases, specific cell types can be removed from blood and transplanted into patients. The process of removing white blood cells for the treatment of leukemia is called apheresis.
This study will make available blood cell collections from volunteers genetically matched to various degrees with recipients in order to test and, if necessary, refine the process of removing white blood cell T-lymphocytes.
|Condition or disease|
|Graft vs Host Disease Hematologic Neoplasm|
|Study Type :||Observational|
|Actual Enrollment :||14 participants|
|Official Title:||Apheresis of Family Members of Patients Undergoing Allogeneic Bone Marrow Transplantation. A Pre-Clinical Study of Selective Depletion of Donor Lymphocytes to Prevent Acute Graft-Versus-Host Disease|
|Study Start Date :||February 2, 1999|
|Study Completion Date :||March 2, 2018|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001872
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||A. John Barrett, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|